Kessler Foundation Presents Data on Ekso(TM) at World Congress of Biomechanics
July 22 2014 - 7:00AM
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton
company, announced today that Kessler Foundation, a global leader
in rehabilitation research, has presented preliminary data at World
Congress of Biomechanics held in Boston, MA, July 5-10, showing
that spinal cord injury (SCI) motor incomplete and complete users
were able to actively increase step swing time, stride length and
hip extension after walking with an Ekso™ robotic exoskeleton. Most
notably, muscle activation per gait cycle increased with training
and became more similar to able-bodied walking.
In an additional study, Kessler Foundation also reports on work
focused on mathematically simulating human and exoskeleton
interactions. The model will be useful in understanding the results
of their on-going studies of intensive exoskeleton training.
Kessler Foundation has been using Ekso Bionics' exoskeleton for
clinical research in patients with spinal cord injury since October
2011 and recently acquired a second device to study utility and
efficacy specifically for stroke survivors.
"We are seeing that robotics in rehabilitation are having an
increasingly positive impact on patient outcomes, and research such
as this is key to furthering such progress," said Rodger DeRose,
president and chief executive officer of Kessler Foundation.
"Exploring robotic exoskeletons is an exciting new avenue for our
mobility researchers."
Ekso Bionics Chief Executive Officer Nathan Harding added, "It
is very interesting to see that muscle activity increased in a
patient with a complete spinal cord injury as they got more
training. They will need more data, but this is a very intriguing
result."
Ekso Bionics designs, develops, and commercializes exoskeletons,
or wearable robots, which have a variety of applications in the
medical, military, industrial, and consumer markets. Exoskeletons
are ready-to-wear, battery-powered robots that are strapped over
the user's clothing, enabling individuals to achieve mobility,
strength, and endurance not otherwise possible. Ekso Bionics' lead
product, EksoTM, is a wearable bionics suit that enables
individuals with any amount of lower extremity weakness to stand up
and walk over ground. Ekso is forging a new frontier in
rehabilitation for people living with the consequences of stroke,
spinal cord injury and other neurological conditions affecting
gait.
About Kessler Foundation
Kessler Foundation, a major nonprofit organization in the field
of disability, is a global leader in rehabilitation research that
seeks to improve cognition, mobility and long-term outcomes,
including employment, for people with neurological disabilities
caused by diseases and injuries of the brain and spinal cord.
Kessler Foundation leads the nation in funding innovative programs
that expand opportunities for employment for people with
disabilities. For more information, visit
KesslerFoundation.org.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of
robotic exoskeletons, or wearable robots, to augment human
strength, endurance and mobility. The company's first commercially
available product called Ekso has helped thousands of people living
with paralysis take millions of steps not otherwise possible. By
designing and creating some of the most forward-thinking and
innovative solutions for people looking to augment human
capabilities, Ekso Bionics is helping people rethink current
physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on
the OTC QB under the symbol EKSO. To learn more about Ekso Bionics
please visit us at www.eksobionics.com
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives
relating to the design, development and commercialization of human
exoskeletons, (ii) a projection of income (including income/loss),
earnings (including earnings/loss) per share, capital expenditures,
dividends, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not
meant to predict or guarantee actual results, performance, events
or circumstances and may not be realized because they are based
upon the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing, the significant length of time and resources
associated with the development of our products and related
insufficient cash flows and resulting illiquidity, the Company's
inability to expand the Company's business, significant government
regulation of medical devices and the healthcare industry, lack of
product diversification, volatility in the price of the Company's
raw materials, existing or increased competition, results of
arbitration and litigation, stock volatility and illiquidity, and
the Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC at
http://www.sec.gov. The Company does not undertake to update these
forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024